• ABOUT 828 MILLION ADULTS AROUND THE WORLD HAV DIABETES, AND 90% HAVE TYPE 2 DIABETES.
  • Only about 5% of People with Type 2 Diabetes Will Achieve Remission.
  • A New Study has found a combination of an SGLT-2 inhibitor Drug and A Moderately Calno-Reprotive Diet Provides Higher Rates of Type 2 Diabetes Remission Comparked to Just Calorie Restriction Alone.

Researchers Estimate That About 828 million adults Around the World Live with Diabetes, with 90% of them Having Type 2 Diabetes.

Recent Studies Predict The Number of People Globally Living With Diabetes Will Grow To At Least 1.3 Billion By 2050.

While Type 2 Diabetes Can Be Managed With Medications and Lifestyle Changes, Only About 5% of People With This Form of Diabetes Will Ever Achieve Disease Remission.

“Diabetes has been as an incurable illness and is dependent on medication for (a) life,” Xiaoying Li, MD, PhD, Professor and Director of the Department of Endocrinology and Metabolism at Zhongshan Hospital Fudan University in China Explained to Medical News Today.

“Diabetes complications gradually occuru as progress diabetes. Thus, it is important to find a Strategy to stop the progression of diabetes for prevention of the complications, ”I have added.

LI is the lead author of a new study recently published in The BMJWHICH FOUND THAT THE COMBINATION OF A SODIUM GLUCOSE COTRANSPORTER 2 (SGLT-2) DRUG INHIBITOR-COMMONLY USED TO TREAT TYPE 2 DIABETES-with A MODERELY CALORIE-STRUCTURE DIET DIET PROVIDES HIGHER RATES OF REMISSION COMPART TO JUSTIFICE.

This Study Received Funding from Biopharmaceutical Company Astrazeneca.

Treatment Diabetes: Why Focus on Dapagliflozin Plus Heat Restriction?

For This Study, Focused on the SGLT-2 Dapagliflozin, and How It Worked in Combination with by Calorie-Restricted Diet.

“SGLT-2 Inhibits are a Class of Medications That Inhibit Glucose Reabsorption From Nephron and increase glucose loss from the urine, ”Li Explanned. “It has been reported that body weight reduction in type 2 (diabetes) patients with overweight or obesity is associated with diabetes remission by bariatric surgery and see Low heat restriction.”

“We Hypothesized that SGLT-2 Inhibitor Plus moderate heat restriction could Achieve More Body Weight Reduction,” I have continued. “On the other hand, SGLT-2 could produces more metabolic benefits and remodel metabolic state, which could help (improve) insulin resistance and beta cell function.”

To behavior the study, Recruited 328 People Between The Ages of 20-70 from China Who Had Type 2 Diabetes For More than 6 Years and Visited Medical Centers from June 2020 to January 2023.

All Study Participants had a starting body mass index (BMI) Greater than 25, and were not taking any diabetes medications other Than Metformin.

Scientists Randomly Assigned participants into Two Groups-One Taking Dapagliflozin with A Moderate Heat-recovered Diet, and One Taking A placebo and following the diet.

The Calorie-Restrict Diet Lowered Participants’ Normal Daily Calories Between 500-750 Kilocalories (Kcal).

Study participants were Asked To Keep A Detailed Food Journal and finded to take part in 150 Minutes of Brisk Walking Each Week Or More than 10,000 Steps Each Day.

They Also Received Dietary Counseling from Dietedias on A Monthly Basis, as well as Messages or Phone Calls Every 2 Weeks for the first 6 months, to Help Support Them.

SGLT-2 Plus Heat Restriction: 44% ACHIEVE DIABETES REMISSION

UPON ANALYSIS, LI AND HIS TEAM FOUNT THAT AFTER 12 months, 44% of Study Participants in the Combination Dapagliflozin and Calorie Restriction Group Achieded Type 2 Diabetes Remission, Compared to 28% in the placebo Group.

“The Remision Rate in Patients Review Dapagliflozin Plus Heat Restriction (44%) is significantly Greater Than Those Review Heat Restriction Alone (28%),” Li Detailed.

“The Chance to Achieve Diabetes Remission in Patients Review Dapagliflozin Plus Heat Restriction Is Incredase By 56%, as shared with tose Receiving Heat Restriction Alone,” HE NOTIED.

Rebecchers Also Discovered That Participants in the Combination Dapagliflozin Group Also experience Systolic Blood Pressureand cholesterol Levels.

“It is thought that those metabolic changes including body weight, insulin resistance, body fat mass, and systolic Blood pressure are associated with with improvement of cardiovascular outcomes and kidney outcomes, which are possibly associated with diabetes remission” Li Said.

Treatment diabetes: collecting the potential of Dapagliflozin

MNT Spoke with Jennifer Cheng, Do, Chief of Endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, About This Study.

“It Makes Sense That A Diabetes Medication, Dapagliflozin, With Calorie Restriction Would Achieve Better Remission for Type 2 Diabetes than Calorie Restriction Alone,” Cheng, Who Was Not Involved in The Study, explained.

“Dapagliflozin is a SGLT-2 Class of Medication, which Helps Your Kidneys stir brush sugar from your Blood Through urination. At Times, It also enables Mild Weight Loss, ”She Noted.

“It is undrasticable that This May Cause Better Glucose Control for People Who Are Taking The Medication,” She continues. “More and More People Are Starting Dapagliflozin for Heart Failure, and other indications, so it is good to know that sugar control May occur as a side effect for patients Who are taking it for other indications.”

“Diabetes is an under-greenery Disease that Many People do Not Even they have,” Cheng Added. “It can cause significant Health Burden as well as Financial Burden If Left Untread. It is important to obtain new treatments scholause of the significant finance burden that diabetes may present for patients. Early Treatment and Better Control of Diabetes Prevents Complications of Diabetes Later in Life. “

SGLT-2 and GLP-1 Combo: The Next Step in Diabetes Research?

MNT Also Spoke with Pouya Shafipour, MD, A Board-Certified Family and Obesity Medicine Physician at providence Saint John’s Health Center in Santa Monica, CA, About This Study.

Shafipour, who was also not involved in the research, commented that he was not surprised by its results:

“Diabetes, as we know, is on the rise, so it is a Major Health Issue. It not only Just Impacts Blood Sugar, But also Kidney Function, Heart DiseaseAlzheimer’s (Disease Risk), (The) Eyes, Nervous System, (and) Neuropathyso it almost, from Head to Toe, The Entire Body. ”

“The More We Can Find Efficient Drugs Before People Go On Insulin Becouse Once Subsone Goes On Insulin, Than It’s Almost The End of the Line – If Sub Subson Has Been Diabetic For Too Long (They) Scholarship Insulin Dependent,” I have continued. “The More We Can Find Drugs That Are Vry Effective Earlier On, We Keep The Pancreatic Function When (Improving) Insulin Sensitivity.”

WHEN IT COMES TO THE NEXT Steps in This Type of Research, Shafipour Said There Are Medications in the Research Pipeline which are a Combination of Sglt-2 Drugs and Glucon-Like Peptide-1 (LPG-1) Agonist Receiver. Ozempic and Zepbound Are Both Example of LPG-1 Medications.

“Both of these classs have shown a Lot of Benefits in Terms of Diabetic Control, as Well As Weight Loss,” I explained. “Obviously, The LPG-1s have more weight loss effects, but if we can be submissive that uses BelSe Classses Together, That Would Be Great.”